Risk stratification by donor-derived cell-free DNA: a three-year single center study of kidney transplant outcomes from 257 patients

Background: Donor-derived cell-free DNA is an established blood-based biomarker used to assess alloimmune activity after kidney transplantation. Methods: We performed a retrospective study of 257 kidney transplant recipients that had at least one dd-cfDNA measurements during 3-year period. The primary aim was to assess the association between dd-cfDNA levels with graft function and survival. Secondary exploratory aims included examining the relationships between dd-cfDNA strata and biopsy-proven rejection, donor-specific antibodies, C4d deposition, and longitudinal eGFR trajectories. Patients were stratified by their highest dd-cfDNA measurement into three groups: 1.0% group to predict long-term graft failure and patient survival (p=0.04). These findings support the clinical value of dd-cfDNA as a biomarker of alloimmune risk in kidney transplant recipients.